Tags : Abraxane

Roche’s Tecentriq + CT (abraxane and carboplatin) Receive the US

Shots: The approval is based on P-III IMpower130 study assessing Tecentriq + CT vs CT as monothx. in 681 chemotherapy-naïve patients with stage IV metastatic non-sq NSCLC with no EGFR or ALK genomic tumor aberrations The P-III IMpower130 study results: OS (18.6 vs 13.9 mos.); PFS (7.2 vs 6.5 mos.); safety profile is consistent with […]Read More